Generation of frameshift‑mutated TGFβR2‑specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV‑1/GM‑CSF in a phase 1 study

FMPV-1 is a component of FMPV-3, an investigational cancer-specific vaccine and being developed to activate anti-cancer 
T cell responses targeting frameshift mutations of MSI-H cancers. This first-in-human, phase 1, single centre, open-label study 
included 16 healthy male subjects who received FMPV-1 (0.15 mg/injection) plus granulocyte-macrophage colony-stimu
lating factor (GM-CSF) (0.03 mg/injection) as two separate, co-located, injections on Days 1, 8, 15, 29 and 43. 

Download our publication here.